Vectibix (panitumumab)

P2, N=214, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2025 --> Mar 2026

P2, N=14, Recruiting, Amgen | Not yet recruiting --> Recruiting

Monotherapy with KRAS G12C inhibitors demonstrated an objective response rate of 23%, while combination therapies with agents such as cetuximab and panitumumab showed a higher response rate of 43%. High heterogeneity across studies suggests variability due to small sample sizes and early-phase trial designs. While preliminary data are promising, further large-scale phase III trials are essential to establish these inhibitors as a standard treatment for KRAS G12C-mutant CRC.

Ion Chiricuta" between 2015 and 2024 with first-line FOLFOX/FOLFIRI plus panitumumab...In multivariate analysis, only bNLR remained independently associated with PFS. These results suggest that both baseline and dynamic NLR may serve as low-cost prognostic biomarkers in mCRC patients treated with anti-EGFR therapy.

After receiving capecitabine monotherapy as first-line therapy, S-1 plus irinotecan plus bevacizumab therapy as second-line, trifluridine/tipiracil (FTD/TPI) monotherapy as third-line, and regorafenib monotherapy as fourth-line therapy, the patient received panitumumab monotherapy as fifth-line therapy...After receiving mFOLFOX6 plus panitumumab therapy as first-line therapy, FOLFIRI plus bevacizumab as second-line, he underwent conversion surgery...As third-line therapy, he received pembrolizumab monotherapy...We encountered two patients with mCRC and EGFR gene amplification who responded to panitumumab monotherapy. EGFR gene amplification may be a potential biomarker for anti-EGFR antibodies, regardless of RAS status.

P1, N=5, Terminated, Rutgers, The State University of New Jersey | Active, not recruiting --> Terminated; slow accrual

The clinical development of this combination strategy was discontinued, as brigatinib treatment was not feasible in patients with advanced EGFR-mutated NSCLC resistant to osimertinib.

P2, N=59, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

The analysis included 29 patients who had previously received all standard therapies: fluoropyrimidines, oxaliplatin, and irinotecan (in a multi-agent regimen or sequentially) and bevacizumab (anti-VEGF therapy). In patients with tumors negative for KRAS, NRAS and BRAF mutations, cetuximab or panitumumab (anti-EGFR therapy) were also used...Only minor differences in survival outcomes were noted-likely due to real-world variability in patient characteristics and timing of treatment assessments. However, continued investigation of personalized and sequential treatment strategies that contain anti-angiogenic drugs is warranted to optimize outcomes.

P2, N=24, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2027 --> Nov 2025 | Trial primary completion date: Dec 2026 --> Nov 2025

Eligible patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovorin, oxaliplatin (mFOLFOX)/panitumumab (control group, n = 217) versus modified fluorouracil, leucovorin, oxaliplatin, irinotecan (mFOLFOXIRI)/panitumumab (experimental group, n = 218). Similar proportions of patients in both groups received subsequent lines of therapy (control/experimental: second line 73%/71%, third line 51%/49%, fourth line 31%/32%), as well as nonpalliative locoregional treatments (control/experimental: 16%/16%). Upfront mFOLFOXIRI/panitumumab significantly improves OS compared with mFOLFOX/panitumumab in patients with RAS/BRAF wild-type mCRC.

P1, N=100, Not yet recruiting, M.D. Anderson Cancer Center